Shareholders want a solution to the financial woes that have plagued Bayer AG since its $63 billion 2018 takeover of chemical company Monsanto.
For now, though, CEO Bill Anderson has ruled out a spinoff, instead making changes to the company’s operating model to instigate a turnaround.
1 2
